Cyberkinetics Neurotechnology Systems, Inc., Engages the Investor Relations Group, Inc., of New York.

FOXBOROUGH, Mass. -- Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: CYKN) (Cyberkinetics) today announced that it has engaged The Investor Relations Group, Inc., (IRG) of New York to advise the company on its corporate, financial and public relations.

"We are very pleased to be working with IRG to help us communicate our exciting, cutting-edge advances in neuroscience to investors and the public," stated Timothy Surgenor, President and Chief Executive Officer of Cyberkinetics.

Dian Griesel, Ph.D., founder and Chief Executive Officer of The Investor Relations Group, said, "We welcome the opportunity to communicate to the financial community and the media the extraordinary potential of Cyberkinetics' award-winning technology."

Cyberkinetics is working to leverage its proprietary brain interface technology platform to develop a range of clinical products. Cyberkinetics' BrainGate(TM) System, designed to enable people with severe motor impairment the means to communicate with a computer directly with their thoughts, is currently in use in clinical trials with leading rehabilitation centers in Boston, Massachusetts, Chicago, Illinois, and Providence, Rhode Island. The Company's NeuroPort(TM) device for monitoring brain electrical activity, received FDA 510(k) clearance in April 2005.

About The Investor Relations Group

The Investor Relations Group, Inc., (IRG) founded in 1996, represents select publicly traded companies, with a unique specialization for assisting those in the small-cap sector. IRG arranges one-on-one meetings for its portfolio companies with pre-qualified money managers handling investment portfolios that range from $10 million to $10 billion+ selected from its proprietary contact base of over 33,000 qualified fund managers who have an investing history in small cap stocks. IRG is a full-service corporate communications company offering services for its portfolio companies that include writing all press releases and shareholder communications and serving as primary contact for the investing community. IRG also houses a full-service public relations arm that specializes in building awareness of its companies within the financial and trade media, as well as the public at large. For further information, please visit the company's website at www.investorrelationsgroup.com.

About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, a leader in brain interface technology, is developing products to treat nervous system diseases and disorders by bringing together advances in neuroscience, computer science and engineering. Cyberkinetics' products are based on over ten years of technology development and cutting-edge neuroscience research at leading academic institutions such as Brown University, the Massachusetts Institute of Technology, Emory University, and the University of Utah.

Cyberkinetics has received FDA clearance to market the NeuroPort System, a neural monitor designed for acute inpatient applications and labeled for temporary (less than 30 days) recording and monitoring of brain electrical activity. The NeuroPort System can contribute to the diagnosis and treatment of neurological conditions in patients who have undergone craniotomy by providing neurologists and neurosurgeons a new resource to detect, transmit and analyze neural activity.

Cyberkinetics' BrainGate System is being designed to give severely paralyzed individuals, as well as individuals with motor impairment from a variety of causes, a long-term, direct brain-computer interface for the purpose of communication and control of a computer, assistive devices, and, ultimately, limb movement.

More information is available at www.cyberkineticsinc.com. For specific information about BrainGate(TM) clinical trials please send an email to [e-mail].

Forward-Looking Statements

This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and can be identified by the use of forward-looking terminology such as "may," "will," "believe," "expect," "anticipate" or other comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements and reported results shall not be considered an indication of our future performance. Factors that might cause or contribute to such differences include our limited operating history; our lack of profits from operations; our ability to successfully develop and commercialize our proposed products; a lengthy approval process and the uncertainty of FDA and other governmental regulatory requirements; clinical trials may fail to demonstrate the safety and effectiveness of our products; the degree and nature of our competition; our ability to employ and retain qualified employees; compliance with recent legislation regarding corporate governance, including the Sarbanes-Oxley Act of 2002; as well as those risks more fully discussed in our public filings with the Securities and Exchange Commission, all of which are difficult to predict and some of which are beyond our control.